Platinum-based therapy selects for an angiogenic enriched tumour micro-environment in High Grade Serous Ovarian Cancer
Background:
- Angiogenesis is a key pathological feature of epithelial ovarian cancer (EOC) and anti-angiogenics have dominated the field of drug development in EOC
- There are no clinically approved predictive biomarker to preselect the subgroup of high grade serous ovarian cancer (HGSOC) that will derive benefit from anti-angiogenic therapy
- Relapse post platinum-based therapy is associated with a beneficial response to anti-angiogenics
- Innate and acquired platinum resistance is characterised by upregulation of VEGFa and receptor tyrosine kinase expression that trigger an enriched angiogenic tumour micro-environment
- In-vitro and in-vivo angiogenesis assays demonstrate that platinum resistant cell lines are sensitive to Cediranib and Nintedanib